In a recent study, a combination therapy for the treatment of relapsed or refractory multiple myeloma proved to be as beneficial in routine clinical practice as it did in clinical trials used to support its approval. READ MORE

News

In a recent study, a combination therapy for the treatment of relapsed or refractory multiple myeloma proved to be as beneficial in routine clinical practice as it did in clinical trials used to support its approval.

READ MORE

In a recent study, researchers evaluated the role of autologous stem cell transplantation in patients with multiple myeloma in the context of novel agents.

READ MORE

A recent cost-effectiveness analysis evaluated treatments for relapsed or refractory multiple myeloma from a United States health system perspective.

READ MORE

A recent study identified patient characteristics that help predict poor 3-year survival in newly diagnosed standard-risk multiple myeloma.

READ MORE

Resources

The American Society of Clinical Oncology released a clinical practice guideline update on the role of bone-modifying agents in patients with active symptomatic multiple myeloma.

READ MORE

Conferences

From December 9-12, 2017, the American Society of Hematology hosted its Annual Meeting and Exposition in Atlanta, Georgia. The meeting provided an opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology as well as to network with top minds in the field.

READ MORE